Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HINT1 | P49773 | 4/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | KRAS | P01116 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26067723 | 1.00 | HPGD (0.58) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL1058400 | 1.00 | HPGD (0.58) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL25241066 | 1.00 | HPGD (0.58) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL26067719 | 0.93 | HINT1 (0.58) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL25408278 | 0.93 | HINT1 (0.58) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL7614834 | 0.92 | HPGD (0.59) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL7614827 | 0.92 | HPGD (0.59) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL29750777 | 0.92 | HPGD (0.55) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL27351 | 0.92 | HINT1 (0.59) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL27352 | 0.92 | HINT1 (0.59) | HPGDHINT1NT5ETAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319916-B2 | Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs | CAMP4 THERAPEUTICS CORPORATION (US) | 2025-06-03 | — | — | US | claimed |
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | claimed |
| US-20240368604-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2024-11-07 | — | — | US | claimed |
| US-20240336924-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2024-10-10 | — | — | US | claimed |
| US-12071623-B2 | IL-34 antisense agents and methods of using same | NOGRA PHARMA LIMITED (IE) | 2024-08-27 | — | — | US | claimed |
| EP-4341403-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | Nogra Pharma Limited (IE) | 2024-03-27 | — | — | EP | claimed |
| US-20240093197-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2024-03-21 | — | — | US | claimed |
| CN-117321206-A | IL-34 antisense agents and methods of use thereof | 诺格拉制药有限公司 | 2023-12-29 | — | — | CN | claimed |
| US-20230002770-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2023-01-05 | — | — | US | claimed |
| WO-2022243299-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2022-11-24 | — | — | WO | claimed |
| CN-114835765-B | Synthesis process of 2' -O- (2-methoxyethyl) guanosine | 奥锐特药业(天津)有限公司 | 2022-11-08 | — | — | CN | claimed |
| EP-4058575-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | Nogra Pharma Limited (IE) | 2022-09-21 | — | — | EP | claimed |
| CN-114835765-A | 2 a , Synthesis process of (E) -O- (2-methoxyethyl) guanosine | 奥锐特药业(天津)有限公司 | 2022-08-02 | — | — | CN | claimed |
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124321-A1 | COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY | BIOGEN MA INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260103714-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA AS (DK) | 2026-04-16 | — | — | US | disclosed |
| EP-1185305-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000076554-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-1019539-A1 | COMBINATORIAL ANTISENSE LIBRARY | Oasis Biosciences, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999018238-A1 | COMBINATORIAL ANTISENSE LIBRARY | OASIS BIOSCIENCES, INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336924-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CPS1, CTPS1, CTPS2 | HPGD 4328/4885HINT1 1282/4885NT5E 2363/4885 |
| US-20260124321-A1 | COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MYO1B, SPIN2B | HPGD 4839/4885HINT1 3812/4885NT5E 1508/4885 |
| US-12319916-B2 | Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs | CPS1, CTPS1, CTPS2 | HPGD 4328/4885HINT1 1282/4885NT5E 2363/4885 |
| US-20260103714-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | NAT10, NAT1, NAA40 | HPGD 4533/4885HINT1 540/4885NT5E 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.